We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin<a href="https://solaci.org/en/2017/01/07/see-the-presentations-of-the-2016-chile-sessions/" title="Read more" >...</a>
Courtesy of Dr. Guillermo Migliaro. Coronary angiography and angioplasty via transradial approach are associated with a significant reduction in access site complications, compared with transfemoral and transbrachial access. Moreover, a significant reduction in mortality has been reported for procedures performed via transradial approach vs. transfemoral approach in primary angioplasty. There is a limited number<a href="https://solaci.org/en/2016/12/19/right-vs-left-transradial-access-for-coronary-procedures/" title="Read more" >...</a>
In 2006, the American Heart Association guidelines recommended that carotid revascularization be performed within 2 weeks of stroke based on data from 2 randomized trials on carotid endarterectomy. This study aimed to determine whether the time between the event and revascularization has decreased after these guidelines were issued, and the proportion of patients receiving some sort of revascularization (endarterectomy<a href="https://solaci.org/en/2016/12/19/carotid-revascularization-after-stroke-when-should-it-be-performed/" title="Read more" >...</a>
The FUTURE study, testing the utility of functional revascularization by measuring the fractional flow reserve (FFR), was halted early by its safety committee due to an increased mortality rate at 1 year among patients guided by FFR. In this unexpected unprecedented outcome, 17 patients in the FFR-guided group died at a year of follow-up, compared with 7 patients<a href="https://solaci.org/en/2016/12/01/future-mortality-increase-in-the-ffr-arm-real-or-casual/" title="Read more" >...</a>
The symposium will take place on December 1, 2016, from 10:15 to 11:30, at “Osorno A” Room of Patagónico Hotel in Puerto Varas, in the context of SOLACI Sessions Chile 2016. This event on complex cardiomyopathy is organized by the Society for Cardiovascular Angiography and Interventions (SCAI) together with SOLACI. Moderators are Drs.<a href="https://solaci.org/en/2016/11/23/scai-solaci-symposium-at-chile-sessions-on-complex-caradiomyopathy/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Unprotected left main coronary artery (LMCA) angioplasty has become an important trend in the last few years. One of the most significant unresolved questions about it is whether one stent is better than two in distal lesions, and how is their progress after treatment. This study included 937 patients who<a href="https://solaci.org/en/2016/11/16/bifurcation-lesion-in-distal-left-main-coronary-artery-one-or-two-stents/" title="Read more" >...</a>
Courtesy of Dr. Agustín Vecchia. The link between operator volume and clinical outcomes has been long and widely debated. After years of discussion, there are promoters and detractors. Currently, interventional cardiology societies all over the world classify centers as “high-volume” or “low-volume” using arbitrary parameters, and require training fellows to perform an also arbitrary number of<a href="https://solaci.org/en/2016/10/25/experienced-operators-50-lower-mortality-rates/" title="Read more" >...</a>
Between 10% and 15% of patients admitted with ST-segment elevation myocardial infarction present concurrent coronary chronic total occlusion (CTO) in a non-infarct-related artery, which is associated with increased morbidity and mortality. The EXPLORE (Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) trial evaluated whether patients admitted<a href="https://solaci.org/en/2016/10/12/rechanneling-a-cto-in-a-non-infarct-related-artery-after-primary-pci-yes-or-no/" title="Read more" >...</a>
Bioresorbable Vascular Scaffolds (BVS) could change the paradigm of peripheral angioplasty according to several small studies suggesting these everolimus eluting devices could significantly improve symptoms in patients with intermittent claudication. [plain] Three year outcomes of the ESPRIT I trial, presented at VIVA 2016 (held in Las Vegas) showed there were no new events between<a href="https://solaci.org/en/2016/10/11/bioresorbable-scaffolds-promising-in-peripheral-territory/" title="Read more" >...</a>
In patients with symptomatic peripheral vascular disease, the paclitaxel coated balloon showed superior efficacy at 3 years compared to the conventional balloon, in addition to very good results at one year when tested in the real world outside strict trial inclusion/exclusion criteria. Both the IN.PACT SFA trial and the IN.PACT SFA global registry showed<a href="https://solaci.org/en/2016/10/11/paclitaxel-drug-coated-balloon-in-femoral-effective-at-long-term/" title="Read more" >...</a>